Vol. 4 No. 4 (2024): April
Reimbursement Reviews

Calaspargase Pegol (Asparlas)

decorative image of the issue cover

Published April 2, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses calaspargase pegol (Asparlas), 3,750 units/5 mL (750 units/mL), concentrate for solution for IV infusion
  • Indication : As a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 year to 21 years